How to take Necitumumab

Necitumumab is a800 mg/50 ml (16 mg/ml) single-dose vial solution. Treatment with Necitumumab must be performed under the supervision of a physician qualified in anti-cancer chemotherapyFor the treatment of adults with non-small cell lung cancer, nexituzumab is 800 mg administered intravenously over 60 minutes on days 1 and 8 of each 3-week cycle prior to infusion of gemcitabine and cisplatin, and for the duration of treatment until disease progression or unacceptable toxicity.

Nexituzumab is administered through a vein, and a healthcare provider will inject it into you. The IV infusion will take at least1 hour to complete. The treatment cycle of Nexituzumab is 21 days, and the doctor will decide how long the patient should receive Nexituzumab treatment. For patients who have previously experienced a Grade 1 or 2 infusion-related reaction (IRR), preemptively administer diphenhydramine hydrochloride (or equivalent) before all subsequent nesituzumab infusions; In patients with a second grade 1 or 2 IRR, premedicate all subsequent infusions with diphenhydramine hydrochloride (or equivalent), acetaminophen (or equivalent), and dexamethasone (or equivalent) before each nesituzumab infusion.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.